9 z d; e% N3 `( Z7 F1 S1 B$ I
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:- x5 x v) ] o1 Q! u$ `3 y
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. 3 X( A( z* d. Bhttp://www.ncbi.nlm.nih.gov/pubmed/229681849 H" X' |2 B+ s/ e- i0 J8 G% K6 x
5 h0 {8 k5 z; @: R3 t W5 x
依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制 ) t. o9 D! U& x9 y& G0 zhttp://d.wanfangdata.com.cn/Thesis_Y1770447.aspx